Physician profile
Ayan Chatterjee
NPI 1265845804
$16,973.18
in general payments reported to CMS, 2019-2025
21 companies · $7,437 in 2025
The $7,437 reported for 2025 was more than what 91% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $1,195 · 2021: $1,995 · 2022: $1,501 · 2023: $2,335 · 2024: $1,794 · 2025: $7,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,333 · Consulting Fee: $4,208 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,332.69 |
| Consulting Fee | $4,207.50 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,282.88 | 2020-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Rxsight INC | $4,788.76 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $1,280.16 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Sight Sciences, INC. | $1,215.49 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $828.71 | 2019-2021 | |
| Glaukos Corporation | $542.71 | 2020-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Nova Eye, INC. | $486.71 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $321.37 | 2019-2021 | |
| Omeros Corporation | $218.73 | 2019-2021 | |
| New World Medical,INC. | $190.53 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Abbvie INC. | $164.40 | 2022-2025 | Durysta |
| Aerie Pharmaceuticals, INC. | $131.64 | 2019 | |
| Allergan, INC. | $130.62 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $115.65 | 2023-2025 | Vyzulta, Envista Mx60 Iol, Miebo |
| Harrow Eye, LLC | $87.38 | 2024-2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $56.22 | 2020-2025 | |
| Genentech USA, INC. | $47.05 | 2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $27.05 | 2023 | |
| Amgen INC. | $20.99 | 2025 | Tepezza |
| Dompe US, INC. | $18.89 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayan Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.